Summary Tenascin-C is an extracellular matrix glycoprotein produced in response to epithelial-mesenchymal interactions during organogenesis and tissue remodelling. It has therefore been proposed as a stromal marker for epithelial malignancy. To test this hypothesis, 30 human lung cancers, presenting a variety of clinicopathological features, and six specimens of normal tissue were examined by Western and Northern blotting of tenascin-C protein and mRNA. The results obtained were: (1) elevated tenascin-C expression was detected in all 30 cases by Western blotting, with mRNA increase in 22 of them; (2) mRNA for a large isoform of tenascin-C, including an alternatively spliced sequence, was expressed in lung cancer tissues but not in normal lungs; and (3) metastasis to lymph nodes was frequently found in cases whose tenascin-C was degraded into small fragments. These results suggest that tenascin-C degradation can be used as a marker for metastatic potential of a tumour.
Tenascin-C (TN-C) (Chiquet-Ehrismann et al, 1986 ) is a component of the extracellular matrix (ECM) that has been shown to be involved in tissue interactions during fetal development and oncogenesis. It is a glycoprotein consisting of six disulphide-linked subunits of molecular sizes 190-250 kDa, with different monomer isoforms being generated by alternative splicing (for reviews, see Erickson and Bourdon, 1989; Jones and Copertino, 1996) . Immunohistochemical studies have revealed that TN-C appears at specific times and locations in the embryo and also occasionally in normal adult tissues (for a review, see Sakakura, 1995) . Subsequent to the initial proposal that it might be a stromal marker for epithelial cancers (Mackie et al, 1987) , it has been shown to be expressed at greater levels in malignant than in benign tumours in many organs, with a tendency for increase in advanced stages (Bourdon et al, 1983; Anbazhagen et al, 1990 ; Van Eyken et al, 1990; Vollmer et al, 1990 ; Koukoulis et al, 1991; Sakakura et al, 1991; Borsi et al, 1992) . A high-molecular-weight isoform that is generated by alternative splicing of RNAs of TN-C was found predominantly in breast (Borsi et al, 1992) , prostatic (Ibrahim et al, 1993) and colorectal (Hauptmann et al, 1995) cancers. The appearance of such a large TN-C isoform has been suggested to be of significance for tumour progression. However, in lung cancers, the results obtained so far have been anomalous. Whereas the splicing pattern of TN-C mRNA was found to be altered, the level of expression was variable, with an increase but also at times a decrease being noted (Oyama et al, 1991) .
In the present study, we examined the molecular size of TN-C in human lung cancers using both Western and Northern blotting, in particular concentrating on the relation to clinicopathological features. We could demonstrate expression of a large isoform of The urea extracts (100 jg of protein per lane) were subjected to electrophoresis in 6% SDS-polyacrylamide gels according to the method of Laemmli (1970) . Immunoblotting was performed using the procedure of Khyse-Andersen (Khyse-Andersen, 1984) . The membranes were incubated with blocking solution containing 2% normal rabbit serum for 30 min, then with RCB 1 (final concentration 3.3 mg ml-1) for 60 min, following the avidin-biotin complex (ABC) method. Immunoreactive proteins were visualized by reaction in a solution containing 0.03% (w/v) cobalt chloride, 0.04% 3,3-diaminobenzidine tetrachloride and 0.036% hydrogen peroxide.
Northern blotting and dot blot hybridization
The human TN-C cDNA clone HT24C (nucleotides 6209-7295; Siri et al, 1991) was a kind gift from Dr Zardi, National Cancer Research Institute, Genoa, Italy.
Total RNAs were extracted from the materials by the acid guanidium thiocyanate-phenol-chloroform method (Chomczynski and Sacci, 1987) , electrophoresed (10 jg per lane) in 0.8% agarose/ 2.2 M formaldehyde-denaturing gels and transferred onto Hybond-N filters (Amersham, Buckinghamshire, UK). Blotted membranes were then hybridized with the P32-labelled TN-C probe. For dot blot hybridization, 5-jig aliquots of each RNA were dotted onto Hybond-N filters and hybridized simultaneously in the same way as for Northern blotting.
Immunohistochemistry
Tissues were fixed in phosphate-buffered paraformaldehyde with picric acid and frozen in liquid nitrogen for cryostat sectioning. The sections were immunostained for TN-C as described previously (Ilunga and Lriyama, 1995) using the ABC method.
RESULTS

Expression of large TN-C isoforms in lung tissues
On immunoblotting, TN-C reactive bands sized 190 kDa were observed in all 30 of the lung cancers; bands sized 250 kDa, occasionally accompanied by a 220-kDa band, were observed in 28 cases ( Figure IA, lanes 1-6) . Abundant expression of TN-C mRNA, in comparison with normal lung was demonstrated in 22 of the 30 cases by dot blot hybridization ( Figure IC, lanes 1-5) . The remaining eight cases showed no or little TN-C expression ( Figure IC, lane 6) . On Northern blotting, a 7.5-kb large-size TN-C mRNA isoform was found in 19 cases and a 5.5-kb small-size 
TN-C degradation in lung cancers
Cases were divided into two groups from the migrating patterns of the TN-C molecules on the gels, one showing two or three bands at the same heights as those of the controls (Figure 2A ) and the other exhibiting additional intensely labelled bands lower than 190 kDa ( Figure 2B ). These bands were concluded to be generated by degradation of TN-C. No relationship was found between the histological type and such degradation (Table 1 ). In tumours demonstrating lymph node metastasis, however, lower bands were observed in 6 of 13 cases (46.1%), a significantly higher incidence than in the group without metastasis (5.8%) (P = 0.025, Table 2 ).
Tissue distribution of TN-C demonstrated by immunohistochemistry
Examination of 30 neoplastic tissues by TN-C immunohistochemistry revealed intense and diffuse staining of the fibrous stroma surrounding the neoplastic epithelia in all tumours, regardless of the histological and clinical features. Cases whose TN-C molecules were degraded on the gels did not show any remarkable differences from their non-degraded counterparts ( Figure 3A and B). In the six normal lung specimens, TN-C staining was positive in the bronchial basement membrane and the vascular walls, and was irregularly scattered on the alveolar walls ( Figure 3C ). 
DISCUSSION
In the breast (Koukoulis et al, 1991; Borsi et al, 1992) , prostate (Ibrahim et al, 1993) and colorectum (Hauptmann et al, 1995) , preferential expression of higher-molecular-weight isoforms of TN-C generated by alternative splicing of RNAs has been observed in cancer tissues. In this study, we demonstrated similar results for the majority of lung cancers. Thus, a large 7.5-kb isoform was detected in all 22 cases expressing appreciable levels of TN-C mRNA, while in normal samples only a small 5.5-kb isoform was found. With regard to the activity of the alternatively spliced domain of TN-C, two papers have appeared in the literature reporting an association with down-regulation of focal adhesion of cells (Murphy-Ullrich et al, 1991) and stimulation of corneal cell migration (Kaplony et al, 1991) . Other studies using recombinant fragment of human TN-C have revealed that the alternatively Tenascin-C in lung cancer 101 spliced domain can bind to annexin II on human endothelial cells and promote cell migration (Chung and Erickson, 1994; Chung et al, 1996) . These findings suggest that the larger TN-C molecules may be involved in detachment of cells from the stroma and in cell movement, thus affecting the malignant behaviour of tumour cells. On the other hand, the extracellular matrix (ECM) network forms a tough and highly crosslinked structural skeleton, which may protect against penetration by tumour cells in the tissue. In this regard, a crucial step in tumour invasion is degradation of ECM proteins by proteolytic enzymes. Two papers concerned with degradation of TN-C by matrix metalloproteinase (MMP) have been published. One described the susceptibility of TN-C purified from human melanoma cells (mainly the large isoform) to MMPs-1, -3 and -7 (Imai et al, 1994) . The other reported the variation in small and large isoforms purified from baby hamster kidney (BHK) cells transfected with human TN-C cDNA . Recently, TN-C degradation in tissue was reported by Riley et al (1996) on Western blot analysis of TN-C extracted from normal and degenerate tendons. Only the small isoform was found in normal tendons, while the large isoform was also detected with several proteolytic fragments in degenerate tendons. Here, in lung cancers, we demonstrated several smaller bands of TN-C on Western blots. Although we can not rule out the possibility of spliced variants, the absence of any smaller transcripts than 5.5 kb on the Northern blots strongly suggests the conclusion that these smaller bands are indeed degradation products of TN-C. As MMPs are known to be produced by various tumour cells (Stetler-Stevenson et al, 1993) , it is likely that they are also expressed by lung cancers. The pattern of fragmentation of TN-C found in the present study thus suggests the presence of various types of MMPs.
We found a higher frequency of lymph node metastasis in many cases with degraded TN-C molecules. This indicates that the amount of degraded fragments of TN-C may be related to the degree of dynamic remodelling of cancer tissues. According to Siri et al (1995) , the large isoform is degraded by MMPs-2 and -3, with cleavage occurring inside the alternatively spliced region. Thus, it is extremely important to identify what proteolytic enzymes are active in lung cancers and how they influence the clinicopathological behaviour.
In the present study, strong immunoreactivity was observed in the stroma of all cases of various histological types. In normal lungs, in contrast, weak staining was found in the bronchial basement membrane and vascular walls in line with earlier findings (Soini et al, 1993) . Thus, TN-C positivity is not restricted to malignant neoplasms and is not specific for the cancer tissue, as initially proposed (Mackie et al, 1987) . It rather appears to be present at interfaces between different types of cell dynamics. Invasion fronts clearly represent such interfaces, where cancer cells confront host tissues. During cancer progression, preferential expression and deposition of large isoform TN-C might bring about changes conducive to cell movement. Deposited TN-C is finally digested into small fragments by a variety of MMPs. As it proved to be impossible at the immunohistochemistry level to evaluate the extent of degradation of TN-C molecules, biochemical analyses may be more useful for further clinicopathological assessment of the role that this process plays in malignancy.
ABBREVIATIONS TN-C, tenascin-C; ECM, extracellular matrix; SCC, squamous cell carcinoma; MMP, matrix metalloproteinase
